Request PDF on ResearchGate | On Feb 1, , Hugo Donato and others published Tratamiento con eritropoyetina humana recombinante. Se demostró que el tratamiento con eritropoyetina humana recombinante (EPO rHu) en pacientes en diálisis es altamente efectivo en cuanto a la corrección de. Eritropoyetina humana recombinante para la anemia de la insuficiencia renal crónica en pacientes en prediálisis. This is not the most recent version of this.
|Published (Last):||15 June 2012|
|PDF File Size:||2.79 Mb|
|ePub File Size:||19.31 Mb|
|Price:||Free* [*Free Regsitration Required]|
Beta-erythropoietin administration and blood sampling. Statistical analysis The results were expressed as mean values with standard deviations.
Available for Android and iOS devices. Despite long clinical experience with ESAs, the mechanisms involved in their elimination have not been fully elucidated.
Subscribe to receive email notifications whenever new articles are published. Der Mechanismus der Anaemie bie der endemische Nephropathie. Colombia Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. Eritripoyetina previous studies showed that the kidneys contribute etitropoyetina Epo elimination in a very minor fashion 35 and residual kidney function in patients more than three years on dialysis is most often negligible, it is not expected that renal elimination of Epo could be of any influence.
As the main organs involved in Epo elimination are the kidneys and bone marrow and both kidney function and bone marrow cellularity decrease with age, the authors suggested that age and creatinine influence Epo elimination.
All patients were treated thrice humanz for h bystandard bicarbonate hemodialysis using polysulphone membrane dialyzers. Endemic nephropathy in Yugoslavia. We cannot confirm the completeness, accuracy and currency of the content.
Inflammation and its impact on recombinsnte in chronic kidney disease: Higher dose of erythropoietin for anemia correction in Balkan endemic nephropathy patients. Ingredient matches for Eritropoyetina Humana Recombinante Erythropoietin Erythropoietin is reported as an ingredient of Eritropoyetina Humana Recombinante in the following countries: This means it is still under development and may contain inaccuracies.
Erythropoietin Epo concentration was determined in all samples on the same day by chemiluminescent immunoassay for erythropoietin on an Immulite analyzer Siemens Healthcare Diagnostics. Djukanovic Lj, Radovanovic Z.
Eritropoyetina Humana Recombinante Delta
However, several authors reported no significant differences between anemia in BEN and recombunante kidney diseases. Br J Clin Pharmacol ; Our patients had iron reserves above the upper limit of normal and a similar proportion of subjects from each group used iron supplements. Subscribe to free Drugs. This work was conducted as a part of projects No and funded by the Ministry of Science, Education and Technological Development, Belgrade, Republic of Serbia.
Basal plasma Epo concentration in BEN patients ranged between 7.
Eritropoyetina Humana Recombinante Delta –
Pharmacokinetics For pharmacokinetic analysis the predose plasma level of Epo was subtracted eritropoyetia all postdose levels of Epo for each patient. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients.
Although an impact of age on Epo elimination in our patients cannot be fully excluded, neither age nor other covariates that differed between the groups was found affect Epo elimination in the ANCOVA model. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. All analyses were performed using the SPSS ver. J Eritropyetina Soc Nephrol ; Available for Android and iOS devices.
The predose plasma level of erythropoietin Epo was subtracted from all postdose levels.
Eritropoyetina Humana Recombinante –
Erythropoietin is reported as an ingredient of Eritropoyetina Humana Recombinante Delta in the following countries:. The main limitation of our study was the small number of patients in each group, and they were recombinznte matched in age. Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers.
Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator C. This finding needs to be confirmed in a well-controlled study with a larger sample size.
Clin J Am Soc Nephrol ;1: